The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Selective Tumor Cell Targeting Using Low-Affinity, Multivalent Interactions
Abstract
This report highlights the advantages of low-affinity, multivalent interactions to recognize one cell type over another. Our goal was to devise a strategy to mediate selective killing of tumor cells, which are often distinguished from normal cells by their higher levels of particular cell surface receptors. To test whether multivalent interactions could lead to highly specific cell targeting, we used a chemically synthesized small-molecule ligand composed of two distinct motifs: (1) an Arg-Gly-Asp (RGD) peptidomimetic that binds tightly (Kd approximately 10(-9)M) to alphavbeta3 integrins and (2) the galactosyl-alpha(1-3)galactose (alpha-Gal epitope), which is recognized by human anti-alpha-galactosyl antibodies (anti-Gal). Importantly, anti-Gal binding requires a multivalent presentation of carbohydrate residues; anti-Gal antibodies interact weakly with the monovalent oligosaccharide (Kd approximately 10(-5)M) but bind tightly (Kd approximately 10(-11) M) to multivalent displays of alpha-Gal epitopes. Such a display is generated when the bifunctional conjugate decorates a cell possessing a high level of alphavbeta3 integrin; the resulting cell surface, which presents many alpha-Gal epitopes, can recruit anti-Gal, thereby triggering complement-mediated lysis. Only those cells with high levels of the integrin receptor are killed. In contrast, doxorubicin tethered to the RGD-based ligand affords indiscriminate cell death. These results highlight the advantages of exploiting the type of the multivalent recognition processes used by physiological systems to discriminate between cells. The selectivity of this strategy is superior to traditional, abiotic, high-affinity targeting methods. Our results have implications for the treatment of cancer and other diseases characterized by the presence of deleterious cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mosmann, T. (1983) · Journal of Immunological Methods · doi:10.1016/0022-1759(83)90303-4 · Cited by 56,104
Integrins: Versatility, modulation, and signaling in cell adhesion
Hynes, R. O. (1992) · Cell · doi:10.1016/0092-8674(92)90115-s · Cited by 9,859
New Perspectives in Cell Adhesion: RGD and Integrins
Ruoslahti, E., & Pierschbacher, M. D. (1987) · Science · doi:10.1126/science.2821619 · Cited by 4,865
Mammen, M., Choi, S.-K., & Whitesides, G. M. (1998) · Angewandte Chemie International Edition · doi:10.1002/(sici)1521-3773(19981102)37:20<2754::aid-anie2754>3.0.co;2-3 · Cited by 4,110
Giancotti, F. G., & Ruoslahti, E. (1999) · Science · doi:10.1126/science.285.5430.1028 · Cited by 3,869
Integrins and Signal Transduction Pathways: the Road Taken
Clark, E. A., & Brugge, J. S. (1995) · Science · doi:10.1126/science.7716514 · Cited by 2,937
Integrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels
Brooks, P. C., Montgomery, A. M. P., Rosenfeld, M., Reisfeld, R. A., Hu, T., Klier, G., & Cheresh, D. A. (1994) · Cell · doi:10.1016/0092-8674(94)90007-8 · Cited by 2,262
Cancer Treatment by Targeted Drug Delivery to Tumor Vasculature in a Mouse Model
Arap, W., Pasqualini, R., & Ruoslahti, E. (1998) · Science · doi:10.1126/science.279.5349.377 · Cited by 2,054
Xiong, J.-P., Stehle, T., Zhang, R., Joachimiak, A., Frech, M., Goodman, S. L., & Arnaout, M. A. (2002) · Science · doi:10.1126/science.1069040 · Cited by 1,613
Plow, E. F., Haas, T. A., Zhang, L., Loftus, J., & Smith, J. W. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.r000003200 · Cited by 1,356
Definition of Two Angiogenic Pathways by Distinct α v Integrins
Friedlander, M., Brooks, P. C., Shaffer, R. W., Kincaid, C. M., Varner, J. A., & Cheresh, D. A. (1995) · Science · doi:10.1126/science.270.5241.1500 · Cited by 1,321
Arming antibodies: prospects and challenges for immunoconjugates
Wu, A. M., & Senter, P. D. (2005) · Nature Biotechnology · doi:10.1038/nbt1141 · Cited by 1,052
Synthetic Multivalent Ligands as Probes of Signal Transduction
Kiessling, L. L., Gestwicki, J. E., & Strong, L. E. (2006) · Angewandte Chemie International Edition · doi:10.1002/anie.200502794 · Cited by 864
Self-citationGalili, U., Shohet, S. B., Kobrin, E., Stults, C. L., & Macher, B. A. (1988) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)77900-9 · Cited by 817
αv Integrins as receptors for tumor targeting by circulating ligands
Pasqualini, R., Koivunen, E., & Ruoslahti, E. (1997) · Nature Biotechnology · doi:10.1038/nbt0697-542 · Cited by 744
A unique natural human IgG antibody with anti-alpha-galactosyl specificity.
Galili, U., Rachmilewitz, E. A., Peleg, A., & Flechner, I. (1984) · The Journal of experimental medicine · doi:10.1084/jem.160.5.1519 · Cited by 631
Anti-pig IgM antibodies in human serum react predominantly with Gal(alpha 1-3)Gal epitopes.
Sandrin, M. S., Vaughan, H. A., Dabkowski, P. L., & McKenzie, I. F. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.23.11391 · Cited by 605
Galili, U., Clark, M. R., Shohet, S. B., Buehler, J., & Macher, B. A. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.5.1369 · Cited by 549
A reevaluation of integrins as regulators of angiogenesis
Hynes, R. O. (2002) · Nature Medicine · doi:10.1038/nm0902-918 · Cited by 548
Galili, U., Mandrell, R. E., Hamadeh, R. M., Shohet, S. B., & Griffiss, J. M. (1988) · Infection and Immunity · doi:10.1128/iai.56.7.1730-1737.1988 · Cited by 548
Synthetic multivalent ligands in the exploration of cell-surface interactions
Kiessling, L. (2000) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(00)00153-8 · Cited by 544
Self-citationTemming, K., Schiffelers, R. M., Molema, G., & Kok, R. J. (2005) · Drug Resistance Updates · doi:10.1016/j.drup.2005.10.002 · Cited by 467
Meyer, A., Auernheimer, J., Modlinger, A., & Kessler, H. (2006) · Current Pharmaceutical Design · doi:10.2174/138161206777947740 · Cited by 291
Membrane proteins that protect against complement lysis
Morgan, B. P., & Meri, S. (1994) · Springer Seminars in Immunopathology · doi:10.1007/bf01837366 · Cited by 263
Recognition Specificity of Neoglycopolymers Prepared by Ring-Opening Metathesis Polymerization
Mortell, K. H., Weatherman, R. V., & Kiessling, L. L. (1996) · Journal of the American Chemical Society · doi:10.1021/ja953574q · Cited by 261
Self-citationThe α-gal epitope (Galα1-3Galβ1-4GlcNAc-R) in xenotransplantation
Galili, U. (2001) · Biochimie · doi:10.1016/s0300-9084(01)01294-9 · Cited by 212
Characterization and affinity isolation of xenoreactive human natural antibodies.
Parker, W., Bruno, D., Holzknecht, Z. E., & Platt, J. L. (1994) · The Journal of Immunology · doi:10.4049/jimmunol.153.8.3791 · Cited by 209
Paul Ehrlich — in search of the magic bullet
Winau, F., Westphal, O., & Winau, R. (2004) · Microbes and Infection · doi:10.1016/j.micinf.2004.04.003 · Cited by 164
Miller, W. H., Keenan, R. M., Willette, R. N., & Lark, M. W. (2000) · Drug Discovery Today · doi:10.1016/s1359-6446(00)01545-2 · Cited by 102
de Groot, F. M. H., Broxterman, H. J., Adams, H. P. H. M., van Vliet, A., TESSER, G. I., Elderkamp, Y. W., Schraa, A. J., Kok, R. J., Molema, G., Pinedo, H. M., et al. (2002) · PubMed · Cited by 86
Bifunctional Ligands that Target Cells Displaying the αvβ3 Integrin
Owen, R. M., Carlson, C. B., Xu, J., Mowery, P., Fasella, E., & Kiessling, L. L. (2006) · ChemBioChem · doi:10.1002/cbic.200600339 · Cited by 69
Self-citationDoxorubicin-formaldehyde conjugates targeting alphavbeta3 integrin.
Burkhart, D. J., Kalet, B. T., Coleman, M. P., Post, G. C., & Koch, T. H. (2004) · PubMed · Cited by 69
Doxorubicin-formaldehyde conjugates targeting αvβ3 integrin
Burkhart, D. J., Kalet, B. T., Coleman, M. P., Post, G. C., & Koch, T. H. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1593.3.12 · Cited by 64
Dickerson, E. B., Akhtar, N., Steinberg, H. N., Wang, Z., Lindstrom, M. J., Padilla, M. L., Auerbach, R., & Helfand, S. C. (2004) · Molecular Cancer Research · doi:10.1158/1541-7786.663.2.12 · Cited by 64
Wang, J.-Q., Chen, X., Zhang, W. Y., Zacharek, S. J., Chen, Y., & Wang, P. G. (1999) · Journal of the American Chemical Society · doi:10.1021/ja990219h · Cited by 63
Redirecting the immune response: ligand-mediated immunogenicity
Shokat, K. M., & Schultz, P. G. (1991) · Journal of the American Chemical Society · doi:10.1021/ja00005a077 · Cited by 61
Wieslander, J., M�nsson, O., Kallin, E., Gabreilli, A., Nowack, H., & Timpl, R. (1990) · Glycoconjugate Journal · doi:10.1007/bf01050405 · Cited by 58
Dickerson, E. B., Akhtar, N., Steinberg, H. N., Wang, Z. Y., Lindstrom, M. J., Padilla, M. L., Auerbach, R., & Helfand, S. C. (2004) · PubMed · Cited by 57
Allman, R., Cowburn, P., & Mason, M. D. (2000) · European Journal of Cancer · doi:10.1016/s0959-8049(99)00279-8 · Cited by 56
Perspectives on complement in xenotransplantation
Mollnes, T. E. (2003) · Molecular Immunology · doi:10.1016/s0161-5890(03)00106-8 · Cited by 32
Cited by
Nanoparticle therapeutics: an emerging treatment modality for cancer
Davis, M. E., Chen, Z., & Shin, D. M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2614 · Cited by 4,233
Nanoparticle Size and Surface Chemistry Determine Serum Protein Adsorption and Macrophage Uptake
Walkey, C. D., Olsen, J. B., Guo, H., Emili, A., & Chan, W. C. W. (2012) · Journal of the American Chemical Society · doi:10.1021/ja2084338 · Cited by 1,926
Block copolymer micelles in nanomedicine applications
Cabral, H., Miyata, K., Osada, K., & Kataoka, K. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00199 · Cited by 1,309
Biodegradable dendritic positron-emitting nanoprobes for the noninvasive imaging of angiogenesis
Almutairi, A., Rossin, R., Shokeen, M., Hagooly, A., Ananth, A., Capoccia, B., Guillaudeu, S., Abendschein, D., Anderson, C. J., Welch, M. J., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811757106 · Cited by 235
Unifying principles of bifunctional, proximity-inducing small molecules
Gerry, C. J., & Schreiber, S. L. (2020) · Nature Chemical Biology · doi:10.1038/s41589-020-0469-1 · Cited by 199
Metadata
- Authors
- Carlson, C. B., Mowery, P., Owen, R. M., Dykhuizen, E. C., & Kiessling, L. L.
- Venue
- ACS Chemical Biology
- Publisher
- American Chemical Society (ACS)
- Published
- 2007-01-26
- Volume
- 2
- Issue
- 2
- Pages
- 119-127
- ISSN
- 1554-8929 (ISSN-L)
- 1554-8937
- OpenAlex
- W1971969520
- Cited by
- 270
- References
- 40
- FWCI
- 11.73
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.